• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. AstraZeneca licenses Cancer Drug Zoladex to TerSera for the US, Canada

    AstraZeneca licenses Cancer Drug Zoladex to TerSera for the US, Canada

  2. AstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq Gets FDA Approval

    AstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq Gets FDA Approval

  3. AstraZeneca Trial For Breast Cancer Treatment Shows Positive Results

    AstraZeneca Trial For Breast Cancer Treatment Shows Positive Results

  4. Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

    Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

  5. Unilever Chief Raises the Defenses as Kraft Heinz Circles

    Unilever Chief Raises the Defenses as Kraft Heinz Circles

  6. Kraft Withdraws $143 Billion Offer for Unilever -- 3rd Update

    Kraft Withdraws $143 Billion Offer for Unilever -- 3rd Update

  7. Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 - Research and Markets

    Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 - Research and Markets

  8. UPDATE: FTSE 100 inches lower after U.K. retail sales disappoint

    UPDATE: FTSE 100 inches lower after U.K. retail sales disappoint

  9. UPDATE: FTSE 100 inches lower after U.K. retail sales disappoint

    UPDATE: FTSE 100 inches lower after U.K. retail sales disappoint

  10. LONDON MARKETS: FTSE 100 Steps Higher As Pound Falls On Disappointing U.K. Retail Sales

    LONDON MARKETS: FTSE 100 Steps Higher As Pound Falls On Disappointing U.K. Retail Sales

12345

©2017 Morningstar Advisor. All right reserved.